DDInter1828 DDInter915
Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Tolbutamide {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Tolbutamide {u} (Compound) downregulates {v} (Gene) ATP6V0B
ATP6V0B {u} (Gene) is downregulated by {v} (Compound) Procaterol
Procaterol {u} (Compound) resembles {v} (Compound) Indacaterol
Tolbutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydrocortisone
Hydrocortisone {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Indacaterol
Tolbutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexamethasone
Dexamethasone {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Indacaterol
Tolbutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydrocortisone
Hydrocortisone {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Indacaterol
Tolbutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexamethasone
Dexamethasone {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Indacaterol
Tolbutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydrocortisone
Hydrocortisone {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Tolbutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexamethasone
Dexamethasone {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Tolbutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Formoterol
Formoterol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Adrenergic beta2-Agonists {u} (Pharmacologic Class) includes {v} (Compound) Indacaterol
Tolbutamide {u} (Compound) upregulates {v} (Gene) TLR4
TLR4 {u} (Gene) is associated with {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Indacaterol
Tolbutamide (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Indacaterol (Compound)
Tolbutamide (Compound) downregulates ATP6V0B (Gene) and ATP6V0B (Gene) is downregulated by Procaterol (Compound) and Procaterol (Compound) resembles Indacaterol (Compound)
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) treats asthma (Disease) and asthma (Disease) is treated by Indacaterol (Compound)
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) treats asthma (Disease) and asthma (Disease) is treated by Indacaterol (Compound)
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indacaterol (Compound)
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indacaterol (Compound)
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Indacaterol (Compound)
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Indacaterol (Compound)
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class) and Adrenergic beta2-Agonists (Pharmacologic Class) includes Indacaterol (Compound)
Tolbutamide (Compound) upregulates TLR4 (Gene) and TLR4 (Gene) is associated with asthma (Disease) and asthma (Disease) is treated by Indacaterol (Compound)